Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 15 recruiting now early-phase tilt

Cocaine Use Disorder: early-phase trial registry

15 of 27 indexed Cocaine Use Disorder trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #598 of 28,707 conditions by registered trial count.

27 US clinical trials · 15 currently recruiting · #598 of 28,707 conditions by registered trial count

Cocaine Use Disorder: 27 US clinical trials tracked, 15 recruiting.

Cocaine Use Disorder is the subject of 27 registered US clinical trials on ClinicalTrials.gov, 15 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 17 in Phase 1-2 (earlier-stage). The most active sponsor is The University of Texas Health Science Center, Houston, running 4 of these trials.

Enrollment posture brief

Registry condition cocaine-use-disorder

OPEN 15 | RECR 56% | LATE 1 | EARLY 17 | RANK #598 | SPON 4

Nearest open-share peer: Acute Lymphoblastic Leukemia, Pediatric (56% recruiting · 9 trials)

Cocaine Use Disorder (this)56%Alopecia Areata55.6%Acute Ischemic Stroke44.4%Adenocarcinoma25.9%Acne22.2%
Open-enrollment share among volume-matched conditions near Cocaine Use Disorder

Cocaine Use Disorder lists 15 open slots (56% of 27 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Cocaine Use Disorder on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Cocaine Use Disorder is recruiting above its size-band peers.

    15 of 27 indexed trials (55.6%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Cocaine Use Disorder trials is spread across many organizations.

    The University of Texas Health Science Center, Houston accounts for 4 of 27 trials (14.8%). 17 distinct sponsors appear on at least one study for this condition label.

  3. Most Cocaine Use Disorder trials plan to enrol fewer than 100 people.

    Median target enrolment is 51 among the 27 trials that report a genuine target (sentinel values excluded). 20 of those (74.1%) plan for fewer than 100 participants.

  4. Cocaine Use Disorder research is mostly interventional.

    26 interventional and 1 observational studies make up this index (96.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 113Phase 24Phase 31

Open and recent trials

27 total, page 1 of 1

RECRUITING NA 600 participants

Encouraging Abstinence Behavior in a Drug Epidemic: Optimizing Dynamic Incentives

Wake Forest University Health Sciences

NCT04927143

RECRUITING Phase 2 300 participants

Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders

Evon Medics

NCT06434818

RECRUITING NA 252 participants

Cocaine Cue-reactivity Incubation Study

Icahn School of Medicine at Mount Sinai

NCT07091877

RECRUITING Phase 3 240 participants

Treating Polysubstance Use Using a Novel Digital Technology

Friends Research Institute

NCT05766631

RECRUITING NA 120 participants

Transcranial Direct Current Stimulation (tDCS) for Treatment of Cocaine Use Disorder

Icahn School of Medicine at Mount Sinai

NCT07318480

RECRUITING 80 participants

Aberrant Synaptic Plasticity in Cocaine Use Disorder: A 11C-UCB-J PET Study

Yale University

NCT04721418

RECRUITING Early Phase 1 80 participants

Imaging CRF X NOP Interactions in CUD

Rajesh Narendran

NCT05008146

RECRUITING Phase 2 75 participants

Repurposing Semaglutide for the Treatment of Cocaine Use Disorder

The University of Texas Health Science Center, Houston

NCT07227948

RECRUITING NA 75 participants

Identifying Electrophysiological Targets for Transcranial Magnetic Stimulation in Cocaine Use Disorder

The University of Texas Health Science Center, Houston

NCT05986578

RECRUITING Phase 2 60 participants

Pioglitazone as an Adjunct to Cognitive-Behavioral Therapy for Cocaine Relapse Prevention

The University of Texas Health Science Center, Houston

NCT04843046

RECRUITING Phase 2 40 participants

Evaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV

University of Maryland, Baltimore

NCT06691243

RECRUITING Early Phase 1 30 participants

Cocaine and Pentoxifylline (BED IN 47)

William Stoops

NCT07086794

RECRUITING Early Phase 1 30 participants

[C-11]NPA PET-amphetamine in Cocaine Use Disorders

Rajesh Narendran

NCT05011760

RECRUITING Early Phase 1 24 participants

Behavioral Effects of Drugs (Inpatient): 43 (Opioids, Cocaine, n-Acetylcysteine)

William Stoops

NCT05610072

RECRUITING Early Phase 1 10 participants

Safety Profile of Psilocybin for Cocaine Use Disorder

University of California, Los Angeles

NCT06102434

ACTIVE NOT RECRUITING NA 175 participants

Contingency Management for Drug Use: Does Age Matter?

Wake Forest University Health Sciences

NCT05521854

ACTIVE NOT RECRUITING Early Phase 1 51 participants

Targeting Drug Memories With Methylphenidate

Icahn School of Medicine at Mount Sinai

NCT05978167

COMPLETED NA 141 participants

Temporal Window and Episodic Future Thinking in CUD

Virginia Polytechnic Institute and State University

NCT05507814

COMPLETED Phase 1 99 participants

The Effect of Cognitive Enhancement as a Precursor to Computer Based Training for Cognitive Behavioral Therapy (CBT4CBT)

Yale University

NCT02174614

COMPLETED Early Phase 1 49 participants

[11C]NOP-1A and Cocaine Use Disorders

University of Pittsburgh

NCT03348384

COMPLETED NA 35 participants

Neurobehavioral Measurement of Substance Users in Outpatient Treatment Setting

Hunter Holmes Mcguire Veteran Affairs Medical Center

NCT03662529

COMPLETED Phase 1 30 participants

Reinforcing Effects of Cocaine During Phendimetrazine Maintenance

William Stoops

NCT02522325

COMPLETED Phase 1 30 participants

Cocaine Opioid Oxytocin Option - Limited

University of California, San Francisco

NCT02028533

COMPLETED Phase 1 29 participants

Drug Interaction and Self Administration Studies of Compounds for Cocaine Use Disorder

Virginia Commonwealth University

NCT02537873

COMPLETED Phase 1 21 participants

Phase1, STP7 Cocaine Drug-Drug Interaction Study

Stalicla

NCT06273540

COMPLETED Phase 1 17 participants

SXC-2023 Cocaine Interaction Study

National Institute on Drug Abuse (NIDA)

NCT06343532

COMPLETED NA 6 participants

Identifying Electrophysiological Targets for Transcranial Magnetic Stimulation in Cocaine Use Disorder (Pilot Study)

The University of Texas Health Science Center, Houston

NCT05631548

Phase Distribution

PhaseTrial count
Phase 1 13
Phase 2 4
Phase 3 1

Named interventions

Most-linked intervention names on Cocaine Use Disorder records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
8 trials
Sham iTBS Device
2 trials
Semaglutide Drug
2 trials
SXC-2023 Placebo Drug
1 trials
SXC-2023 Drug
1 trials
Cocaine Intravenous (IV) Drug
1 trials
NOP-1A Drug
1 trials
Cocaine Hydrochloride Drug
1 trials

US sites by state

Facility locations filed on Cocaine Use Disorder trials. A trial with sites in several states counts in each.

Texas 4 trials
Virginia 3 trials
Pennsylvania 3 trials
New York 3 trials
Maryland 3 trials
Kentucky 3 trials
Wisconsin 2 trials
Kansas 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Cocaine Use Disorder page

27 registered trials, 15 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Cocaine Use Disorder condition card totals 27 registered trials; most-linked intervention Placebo; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.